Meeting
2022 ASCO Annual Meeting
Mutational landscape and clinical characterization of over 17,000 patients with myeloid malignancies using real-world data.
Authors
Taylor J. Jensen
Laboratory Corporation of America, Durham, NC
Taylor J. Jensen , Grant Hogg , Li Cai , Heidi M. Hoffmann , Kimberly A. Holden , Kerry D. Fitzgerald , Angela Kenyon , Michael Mooney , Sabrina Gardner , Wenjie Chen , Narasimhan Nagan , Deborah Boles , Scott Parker , Tamara J. Richman , Stanley Letovsky , Henry Dong , Steven M. Anderson , Marcia Eisenberg , Anjen Chenn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7022)
DOI
10.1200/JCO.2022.40.16_suppl.7022
Abstract #
7022
Poster Bd #
253
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.
First Author: Maha AT Elsebaie
Poster
2023 ASCO Annual Meeting
Clinical and molecular characteristics of patients with AML with an exceptional response to ivosidenib.
First Author: Justin M. Watts
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2016 ASCO Annual Meeting
Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.
First Author: Maro Ohanian